BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with…